Please assess the completion status of the following clinical trial:

Trial Title: SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.~* Patients must have high-risk neuroblastoma according to COG risk classification at the time of study enrollment.~* Patients must have at least ONE of the following: 1) Recurrent/progressive disease at any time prior to study enrollment, 2) Refractory disease, 3) Persistent disease~* Patients must have at least ONE of the following: 1) Bone disease, 2) Any amount of neuroblastoma tumor cells in the bone marrow, 3) At least one soft tissue lesion that meets criteria for a TARGET lesion.~* Patients must have a Lansky (\< 16 years) or Karnofsky (\> 16 years) score of at least 50~* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.~* Patients must not be receiving any other anti-cancer agents or radiotherapy at the time of study entry or while on study.~* Patients must not be receiving other investigational medications (covered under another IND) within 30 days of study entry or while on study.~* Patients must not be receiving chronic systemic corticosteroids at doses greater than physiologic dosing (inhaled corticosteroids acceptable).~* Patient must meet the organ function requirements as stated in the protocol.~Exclusion Criteria:~* Pregnancy, breast feeding, or unwillingness to use effective contraception during the study.~* Patients status post-allogeneic stem cell transplant are not eligible.~* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.~* Patients with disease of any major organ system that would compromise their ability to withstand therapy.~* Patients who are on hemodialysis.~* Patients with an active or uncontrolled infection.~* Patients with known intraparenchymal brain metastasis at study entry are excluded due to poor CNS penetration of SF1126.~* Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.~* Patient declines participation in NANT 2004-05, the NANT Biology Study.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- SF1126 (Type: OTHER): Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).